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NIH funding for research underlying new cancer therapies
Contemporary discovery and development of cancer
drugs are based on the model that investments in basic
biomedical science will provide insights that can be
translated into new cures. In the USA, basic research is
primarily funded by the National Institutes of Health
(NIH),1 which allocates half of its research budget to
basic science,2 with smaller amounts contributed by
philanthropy, academics, or industry.1 Basic science
is formally defined as the “systematic study directed
toward fuller knowledge or understanding of the
fundamental aspects of phenomena and observable
facts without specific application towards processes
or products in mind”.3 However, science is often useinspired,4 and much of the NIH funding for basic research
comes from institutes with specific health missions.2,4 Is
there a direct link between NIH funding for basic science
and the emergence of new cancer therapies?
The number of new cancer drugs has grown from 4%
of all US Food and Drug Administration (FDA) approvals
in the 1980s to 27% between 2010 and 2018.5 Evidence
shows that this growth has been driven by advances in
basic science,6 and by the maturation of basic research in
areas such as cancer immunology, cancer genetics, and
cell signalling, which mostly originated in the 1970s and
1980s.7
A 2018 study by Cleary and colleagues8 showed that
NIH funding contributed to the research underlying
all 210 new drugs approved by the FDA between 2010
and 2016. This study identified more than 2 million
publications in PubMed related to these 210 drugs
and their 151 biological targets. Of these publications,
more than 600 000 (30%) had US federal government
research support cited in the NIH RePORTER database.9
This support consisted of more than 200 000 project
years of funding from 1985 to 2016, and more than
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US$100 billion in project costs between 2000 and
2016.8 Notably, more than 90% of NIH-funded research
was associated with publications on biological targets
rather than the drugs themselves, and the research was
considered basic science. Conversely, less than 10% of
this funding was associated with research on drugs and
was considered applied or translational science.8
The largest proportion (28%) of new drugs tested in
this study8 were indicated for the treatment of cancer.
From 2010 to 2016, 59 new drugs were approved for
cancer therapy, including 56 antineoplastic drugs and
three products indicated for the management of sideeffects caused by chemotherapy. These 59 products are
associated with 41 distinct biological targets (appendix
pp 1–2). Of the 59 cancer therapies, 49 (83%) were
discovered by screening against a known biological
target (targeted discovery) and 24 (41%) were classified
as first-in-class—ie, the first approved products
associated with that target. The other 10 of 59 (17%)
therapies were originally identified by their biological
activity and subsequently screened for cancer therapy
(phenotypic discovery).
Using the methods and datasets described by
Cleary and colleagues (appendix p 3),8 we identified
711 702 publications in PubMed related to the
59 cancer drugs or their 41 biological targets. Of these,
266 154 (37%) had federal support cited in the NIH
RePORTER database.9 Accounting for publications related
to more than one drug or target, there were 82 539 unique
publications citing NIH support. Only 3936 (5%) of
these unique publications described research related to
the drugs and were classified as applied or translational
research. The other 78 603 (95%) described research on
the drug targets, but not the drugs themselves, and were
classified as basic research.

See Online for appendix
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For the NCI budget allocation
see https://officeofbudget.od.
nih.gov/approp_hist.html
For the RCDC cancer research
spending see https://report.nih.
gov/categorical_spending.aspx
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Figure: NIH funding for research underlying cancer drugs approved between
2010 and 2016
Annual costs are shown for research directly related to the drug (known as
applied research) and research directly related to the drug target, but not the
drug itself (known as basic research). The annual costs contributed by the NCI
are shown along with the NCI’s total annual budget allocation, including the
American Recovery and Reinvestment Act of 2009–10 and estimated cancer
research spending according to the RCDC. NCI=National Cancer Institute.
NIH=National Institutes of Health. RCDC=Research, Condition, and Disease
Categorization.

The research reported in these publications was
supported by 116 703 project years of NIH funding
(1985–2016) for basic and applied cancer research,
with costs totalling $63·9 billion between 2000 and
2016. This included 107 644 project years (92%) related
to drug targets with a cost of $54·0 billion (85%), and
9059 project years (8%) related to drugs with a cost of
$9·9 billion (15%; appendix p 4).
The figure shows the time course of NIH funding for
research on cancer drugs or their targets along with
the annual budget allocation for the National Cancer
Institute (NCI) and total NIH funding for cancer research
estimated in the Research, Condition, and Disease
Categorization (RCDC) database. These data show that
the NIH funding for research related to these 59 cancer
drugs or their targets approaches or exceeds the total
budget allocation for the NCI and estimates of total NIH
funding for cancer research from 2008 to 2016.
From 2000 to 2016, the NCI contributed $20·1 billion
to this research underlying these 59 cancer drugs or
their targets, representing 31% of the $63·9 billion
total NIH contribution to research (figure). NCI funding
represented 26% ($14·3 billion of $54·0 billion) of
the total for basic published research related to the
biological targets and 43% ($4·3 billion of $9·9 billion)

of the funding for published applied or translational
research related to the drugs (appendix p 4).
Within the NIH, 13 other institutes contributed more
than $1 billion to research associated with these cancer
drugs or their biological targets (appendix p 5). Several
of these institutes are focused on core or translational
research, such as the National Institute of General
Medical Sciences and the National Center for Research
Resources. Other institutes have distinct disease or
demographic-focused missions, such as the National
Institute of Allergy and Infectious Diseases (NIAID), the
National Heart, Lung, and Blood Institute (NHLBI), and
the National Institute of Diabetes and Digestive and
Kidney Diseases (appendix p 5). Some of the funding
from institutes other than the NCI might be related to
malignancies that affect specific organs or populations
(eg, research on leukaemia from the NHLBI). Much
of the funding that contributed to cancer therapies,
however, probably represents spillover effects from useinspired basic research, designed to gain insights into
other diseases.
An example of spillover effects is the research
underlying the checkpoint inhibitors pembrolizumab
and nivolumab. Both products target the PD-1 protein
and pathways involved in down-regulation of the
immune system and self-tolerance.10 Checkpoint inhi
bitors are designed to reverse PD-1-mediated regulation
of the immune system and promote immunological
rejection of tumour cells.10 NIH funding for basic research
on PD-1 totalled 665 project years and $284 million
from 2000 to 2016. Most of this funding, $149 million
(52%), was provided by NIAID, consistent with NIAID’s
focus on immunology, and represents a spillover into
cancer research. By contrast, of the $7·6 million in NIH
funding for applied or translational research related to
pembrolizumab and nivolumab, $7·1 million (93%) was
provided by the NCI, consistent with NCI’s institutional
focus on cancer therapies.
Spillover effects in the emergence of new cancer
therapies are also evident in the observation that
most project funding associated with drugs approved
for cancer are also associated with drugs approved
for other therapeutic indications. Overall, 43 023
of 116 692 (37%) of the project years associated
with cancer products or their biological targets were
also associated with one or more products in other
therapeutic areas (appendix p 6). Consistent with the
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growing importance of immunology and cell signalling
in cancer therapy, 16 935 of 116 692 (15%) of project
years related to a cancer product were also associated
with an endocrine product, whereas 11 635 (10%) were
associated with an immunological product. In addition,
8867 of 116 692 (8%) project years were shared with
products approved for CNS diseases, 7709 (7%) with
metabolic diseases, 7476 (6%) with cardiovascular
disease, and 7254 (6%) with anti-infective therapies.
This analysis extends the previous observation that
NIH funding contributed to each of the 59 cancer
drugs approved between 2010 and 2016.8 Although
the NCI is traditionally viewed as the primary source
of funding for public-sector cancer research, this
analysis showed that less than a third of NIH funding
for published research related to these 59 cancer drugs
or their biological targets came from the NCI. Most
funding was from other institutes across the NIH,
with the largest contributions coming from institutes
focused on distinct disease or demographic-specific
missions.
This analysis also suggests that the annual NCI budget
allocation and the RCDC estimate of cancer spending
does not accurately reflect the NIH contribution to new
cancer therapies. Further work needs to be directed
at characterising the nature of spillovers between
different disease areas and ensuring that the channels
for communication and collaboration across specialty
research areas are adequate to efficiently translate this

www.thelancet.com/oncology Vol 21 June 2020

diverse and distributed body of research into cures for
disease.
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